Low dose combination steroids control autoimmune mouse hearing loss

Dennis Trune, J. Beth Kempton

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The severe side effects of glucocorticoids prevent long term management of hearing loss. Alternative steroid treatments that minimize or eliminate these effects would significantly benefit therapeutic control of hearing disorders. A steroid treatment study of autoimmune mouse hearing loss was conducted to determine the efficacy of combining aldosterone and prednisolone at low doses. An assessment also was made of low dose fludrocortisone, a synthetic mineralocorticoid that also has a slight glucocorticoid effect. MRL/MpJ-Faslpr mice were tested for baseline ABR thresholds at 3months of age and then treated with aldosterone (3.0μg/kg) or prednisolone (1.0mg/kg) to determine the lowest effective dose of each. Other mice were given the two steroids in combination at doses of Pred 0.5mg+Aldo 1.5μg; Pred 1.0mg+Aldo 3.0μg; or Pred 1.5mg+Aldo 5.0μg. Mice were retested with ABR at 1 and 2months to determine the efficacy of the different steroid treatments in controlling hearing loss. Another series of mice were given the synthetic mineralocorticoid fludrocortisone at low (2.8μg/kg) or high (10μg/kg) doses and retested at monthly intervals for 3months. Autoimmune mouse hearing loss developed in untreated controls. This threshold elevation was not prevented by prednisolone at 1mg/kg or by aldosterone at 3μg/kg when each was given alone. However, the two steroids combined at these doses effectively controlled hearing loss. The fludrocortisone treatments also were effective at low doses in preventing or reversing the autoimmune mouse hearing loss. This efficacy of combined steroids at low doses suggests the potential for reducing the side effects of glucocorticoids in the therapeutic control of hearing disorders.

Original languageEnglish (US)
Pages (from-to)140-145
Number of pages6
JournalJournal of Neuroimmunology
Volume229
Issue number1-2
DOIs
StatePublished - Dec 15 2010

Fingerprint

Hearing Loss
Steroids
Fludrocortisone
Prednisolone
Aldosterone
Hearing Disorders
Glucocorticoids
Mineralocorticoids
Therapeutics
prednylidene

Keywords

  • Adrenocorticosteroids
  • Aldosterone
  • Autoimmune hearing loss
  • Fludrocortisone
  • Inner ear
  • MRL/MpJ-Faslpr autoimmune mice
  • Prednisolone

ASJC Scopus subject areas

  • Immunology
  • Clinical Neurology
  • Immunology and Allergy
  • Neurology

Cite this

Low dose combination steroids control autoimmune mouse hearing loss. / Trune, Dennis; Kempton, J. Beth.

In: Journal of Neuroimmunology, Vol. 229, No. 1-2, 15.12.2010, p. 140-145.

Research output: Contribution to journalArticle

@article{167ee77ba1564599be3dd6b4184d2aa5,
title = "Low dose combination steroids control autoimmune mouse hearing loss",
abstract = "The severe side effects of glucocorticoids prevent long term management of hearing loss. Alternative steroid treatments that minimize or eliminate these effects would significantly benefit therapeutic control of hearing disorders. A steroid treatment study of autoimmune mouse hearing loss was conducted to determine the efficacy of combining aldosterone and prednisolone at low doses. An assessment also was made of low dose fludrocortisone, a synthetic mineralocorticoid that also has a slight glucocorticoid effect. MRL/MpJ-Faslpr mice were tested for baseline ABR thresholds at 3months of age and then treated with aldosterone (3.0μg/kg) or prednisolone (1.0mg/kg) to determine the lowest effective dose of each. Other mice were given the two steroids in combination at doses of Pred 0.5mg+Aldo 1.5μg; Pred 1.0mg+Aldo 3.0μg; or Pred 1.5mg+Aldo 5.0μg. Mice were retested with ABR at 1 and 2months to determine the efficacy of the different steroid treatments in controlling hearing loss. Another series of mice were given the synthetic mineralocorticoid fludrocortisone at low (2.8μg/kg) or high (10μg/kg) doses and retested at monthly intervals for 3months. Autoimmune mouse hearing loss developed in untreated controls. This threshold elevation was not prevented by prednisolone at 1mg/kg or by aldosterone at 3μg/kg when each was given alone. However, the two steroids combined at these doses effectively controlled hearing loss. The fludrocortisone treatments also were effective at low doses in preventing or reversing the autoimmune mouse hearing loss. This efficacy of combined steroids at low doses suggests the potential for reducing the side effects of glucocorticoids in the therapeutic control of hearing disorders.",
keywords = "Adrenocorticosteroids, Aldosterone, Autoimmune hearing loss, Fludrocortisone, Inner ear, MRL/MpJ-Faslpr autoimmune mice, Prednisolone",
author = "Dennis Trune and Kempton, {J. Beth}",
year = "2010",
month = "12",
day = "15",
doi = "10.1016/j.jneuroim.2010.07.026",
language = "English (US)",
volume = "229",
pages = "140--145",
journal = "Journal of Neuroimmunology",
issn = "0165-5728",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Low dose combination steroids control autoimmune mouse hearing loss

AU - Trune, Dennis

AU - Kempton, J. Beth

PY - 2010/12/15

Y1 - 2010/12/15

N2 - The severe side effects of glucocorticoids prevent long term management of hearing loss. Alternative steroid treatments that minimize or eliminate these effects would significantly benefit therapeutic control of hearing disorders. A steroid treatment study of autoimmune mouse hearing loss was conducted to determine the efficacy of combining aldosterone and prednisolone at low doses. An assessment also was made of low dose fludrocortisone, a synthetic mineralocorticoid that also has a slight glucocorticoid effect. MRL/MpJ-Faslpr mice were tested for baseline ABR thresholds at 3months of age and then treated with aldosterone (3.0μg/kg) or prednisolone (1.0mg/kg) to determine the lowest effective dose of each. Other mice were given the two steroids in combination at doses of Pred 0.5mg+Aldo 1.5μg; Pred 1.0mg+Aldo 3.0μg; or Pred 1.5mg+Aldo 5.0μg. Mice were retested with ABR at 1 and 2months to determine the efficacy of the different steroid treatments in controlling hearing loss. Another series of mice were given the synthetic mineralocorticoid fludrocortisone at low (2.8μg/kg) or high (10μg/kg) doses and retested at monthly intervals for 3months. Autoimmune mouse hearing loss developed in untreated controls. This threshold elevation was not prevented by prednisolone at 1mg/kg or by aldosterone at 3μg/kg when each was given alone. However, the two steroids combined at these doses effectively controlled hearing loss. The fludrocortisone treatments also were effective at low doses in preventing or reversing the autoimmune mouse hearing loss. This efficacy of combined steroids at low doses suggests the potential for reducing the side effects of glucocorticoids in the therapeutic control of hearing disorders.

AB - The severe side effects of glucocorticoids prevent long term management of hearing loss. Alternative steroid treatments that minimize or eliminate these effects would significantly benefit therapeutic control of hearing disorders. A steroid treatment study of autoimmune mouse hearing loss was conducted to determine the efficacy of combining aldosterone and prednisolone at low doses. An assessment also was made of low dose fludrocortisone, a synthetic mineralocorticoid that also has a slight glucocorticoid effect. MRL/MpJ-Faslpr mice were tested for baseline ABR thresholds at 3months of age and then treated with aldosterone (3.0μg/kg) or prednisolone (1.0mg/kg) to determine the lowest effective dose of each. Other mice were given the two steroids in combination at doses of Pred 0.5mg+Aldo 1.5μg; Pred 1.0mg+Aldo 3.0μg; or Pred 1.5mg+Aldo 5.0μg. Mice were retested with ABR at 1 and 2months to determine the efficacy of the different steroid treatments in controlling hearing loss. Another series of mice were given the synthetic mineralocorticoid fludrocortisone at low (2.8μg/kg) or high (10μg/kg) doses and retested at monthly intervals for 3months. Autoimmune mouse hearing loss developed in untreated controls. This threshold elevation was not prevented by prednisolone at 1mg/kg or by aldosterone at 3μg/kg when each was given alone. However, the two steroids combined at these doses effectively controlled hearing loss. The fludrocortisone treatments also were effective at low doses in preventing or reversing the autoimmune mouse hearing loss. This efficacy of combined steroids at low doses suggests the potential for reducing the side effects of glucocorticoids in the therapeutic control of hearing disorders.

KW - Adrenocorticosteroids

KW - Aldosterone

KW - Autoimmune hearing loss

KW - Fludrocortisone

KW - Inner ear

KW - MRL/MpJ-Faslpr autoimmune mice

KW - Prednisolone

UR - http://www.scopus.com/inward/record.url?scp=78650194663&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650194663&partnerID=8YFLogxK

U2 - 10.1016/j.jneuroim.2010.07.026

DO - 10.1016/j.jneuroim.2010.07.026

M3 - Article

C2 - 20800906

AN - SCOPUS:78650194663

VL - 229

SP - 140

EP - 145

JO - Journal of Neuroimmunology

JF - Journal of Neuroimmunology

SN - 0165-5728

IS - 1-2

ER -